<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00696020</url>
  </required_header>
  <id_info>
    <org_study_id>1237.4</org_study_id>
    <secondary_id>EudraCT No: 2007-005087-26</secondary_id>
    <nct_id>NCT00696020</nct_id>
  </id_info>
  <brief_title>Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)</brief_title>
  <official_title>Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination With 5 Microgram Tiotropium Bromide (Delivered by the Respimat Inhaler) Compared With 5 Microgram Tiotropium Bromide Monoproduct (Delivered by the Respimat Inhaler) in Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL
      administered with 5 micrograms tiotropium bromide solution for inhalation, delivered by the
      Respimat inhaler, once daily for four weeks in patients with chronic obstructive pulmonary
      disease (COPD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough FEV1 Response [L] After 4 Weeks of Treatment</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Trough FEV1 (Forced expiratory volume in 1 second) was defined as the mean of the two FEV1 values (performed at 1 h and 10 min prior to study medication inhalation) at the end of the dosing interval, 24 hours post-drug administration. Trough FEV1 response was defined as the change from baseline in trough FEV1. Baseline FEV1 was defined as the mean of the 2 pre-treatment FEV1 values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on ANCOVA with terms for baseline, treatment, and centre (centre random, all other effects fixed).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response [L] After 1 and 2 Weeks of Treatment.</measure>
    <time_frame>Baseline, 1 week and 2 weeks</time_frame>
    <description>Trough FEV1 (forced expiratory volume in 1 second) was defined as the mean of the 2 FEV1 values (performed at 1 h and 10 min prior to study medication inhalation) at the end of the dosing interval, 24 hours post-drug administration. Trough FEV1 response was defined as the change from baseline in trough FEV1. Baseline FEV1 was defined as the mean of the 2 pre-treatment FEV1 values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response [L] After 1, 2 and 4 Weeks of Treatment</measure>
    <time_frame>Baseline, 1 week, 2 weeks and 4 weeks</time_frame>
    <description>Trough FVC (forced vital capacity) was defined as the mean of the 2 FVC values (performed at 1 h and 10 min prior to study medication inhalation) at the end of the dosing interval, 24 hours post-drug administration. Trough FVC response was defined as the change from baseline in trough FVC. Baseline FVC was defined as the mean of the 2 pre-treatment FVC values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC(0-3h) Response [L] After First Administration and After 1, 2 and 4 Weeks of Treatment</measure>
    <time_frame>1 h and 10 min prior to inhalation and 5 min (only for week 1 and 2), 30 min, 1 h, 2 h and 3 h after inhalation at baseline and after 1, 2 and 4 weeks</time_frame>
    <description>Response is defined as change from the baseline value. AUC(0-3h) (area under the curve) was calculated as the area under the curve from 0 to 3 hours on the various test days using the trapezoidal rule, divided by the full duration (3 hours) to report in litres. Baseline FEV1 was defined as the mean of the 2 pre-treatment FEV1 values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC(0-3h) Response [L] After First Administration and After 1, 2 and 4 Weeks of Treatment.</measure>
    <time_frame>1 h and 10 min prior to inhalation and 5 min (only for week 1 and 2), 30 min, 1 h, 2 h and 3 h after inhalation at baseline and after 1, 2 and 4 weeks</time_frame>
    <description>FVC (forced vital capacity) AUC(0-3h) response is defined as change from the baseline value. AUC(0-3h) was calculated as the area under the curve from 0 to 3 hours on the various test days using the trapezoidal rule, divided by the full duration (3 hours) to report in litres. Baseline FVC was defined as the mean of the 2 pre-treatment FVC values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF AUC(0-3h) Response [L/Min] After First Administration and After 1, 2 and 4 Weeks of Treatment.</measure>
    <time_frame>1 h and 10 min prior to inhalation and 5 min (only for week 1 and 2), 30 min, 1 h, 2 h and 3 h after inhalation at baseline and after 1, 2 and 4 weeks</time_frame>
    <description>PEF (peak expiratory flow rate L/min) AUC(0-3h) response is defined as change from the baseline value. AUC(0-3h) will be calculated as the area under the curve from 0 to 3 hours on the various test days using the trapezoidal rule, divided by the full duration (3 hours) to report in litres/min. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC(0-6h) Response [L] After 4 Weeks of Treatment</measure>
    <time_frame>1 h and 10 min prior to inhalation at baseline and after 4 weeks and 30 min, 1 h, 2 h, 3 h, 4 h, 5 h and 6h after inhalation at baseline and after 4 weeks (Day 29)</time_frame>
    <description>FEV1 (forced expiratory volume in 1 second) AUC(0-6h) response is defined as change from the baseline value. AUC(0-6h) will be calculated as the area under the curve from 0 to 6 hours on test day 29 using the trapezoidal rule, divided by the full duration (6 hours) to report in litres. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on ANCOVA with terms for baseline, treatment, and centre (centre random, all other effects fixed).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC(0-6h) Response [L] After 4 Weeks of Treatment</measure>
    <time_frame>1 h and 10 min prior to inhalation at baseline and after 4 weeks and 30 min, 1 h, 2 h, 3 h, 4 h, 5 h and 6h after inhalation at baseline and after 4 weeks (Day 29)</time_frame>
    <description>FVC (forced vital capacity) AUC(0-6h) response is defined as change from the baseline value. AUC(0-6h) will be calculated as the area under the curve from 0 to 6 hours on test day 29 using the trapezoidal rule, divided by the full duration (6 hours) to report in litres. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF AUC(0-6h) Response [L] After 4 Weeks of Treatment</measure>
    <time_frame>1 h and 10 min prior to inhalation at baseline and after 4 weeks and 30 min, 1 h, 2 h, 3 h, 4 h, 5 h and 6h after inhalation at baseline and after 4 weeks (Day 29)</time_frame>
    <description>PEF (peak expiratory flow rate L/min) AUC(0-6h) response is defined as change from the baseline value. AUC(0-6h) will be calculated as the area under the curve from 0 to 6 hours on test day 29 using the trapezoidal rule, divided by the full duration (6 hours) to report in litres. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Peak(0-3h) Response [L] After First Administration and After 1, 2 and 4 Weeks of Treatment</measure>
    <time_frame>5 min (only for week 1 and 2), 30 min, 1 h, 2 h and 3 h after inhalation at baseline and after 1 week, 2 weeks and 4 weeks</time_frame>
    <description>FEV1 (forced expiratory volume in 1 second) peak(0-3h) is the maximum post-dose value during the first 3 hours after first administration and after 1, 2 and 4 weeks of treatment. Response is defined as change from the baseline value. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Peak(0-3h) Response [L] After First Administration and After 1, 2 and 4 Weeks of Treatment</measure>
    <time_frame>5 min (only for week 1 and 2), 30 min, 1 h, 2 h and 3 h after inhalation at baseline and after 1 week, 2 weeks and 4 weeks</time_frame>
    <description>FVC (forced vital capacity) peak(0-3h) is the maximum post-dose value during the first 3 hours after first administration and after 1, 2 and 4 weeks of treatment. Response is defined as change from the baseline value. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF Peak(0-3h) Response [L] After First Administration and After 1, 2 and 4 Weeks of Treatment</measure>
    <time_frame>5 min (only for week 1 and 2), 30 min, 1 h, 2 h and 3 h after inhalation at baseline and after 1 week, 2 weeks and 4 weeks</time_frame>
    <description>PEF (peak expiratory flow rate L/min) peak(0-3h) is the maximum post-dose value during the first 3 hours after first administration and after 1, 2 and 4 weeks of treatment. Response is defined as change from the baseline value. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 and PEF (Unsupervised) AUC(0-6h) Response [L] After First Administration and After 1, 2 and 4 Weeks of Treatment</measure>
    <time_frame>After first administration, 1 week, 2 weeks and 4 weeks</time_frame>
    <description>AUC(0-6h) for FEV1, and PEF (unsupervised) were not studied because the pertinent information from the unsupervised pulmonary function tests was for the time interval from 9 to 12 hours post-dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 (Unsupervised) AUC(6-12h) Response [L] After First Administration and 1,2 and 4 Weeks of Treatment</measure>
    <time_frame>6 h, 9 h and 12 h after inhalation at baseline and after 1 week, 2 weeks and 4 weeks</time_frame>
    <description>FEV1 (forced expiratory volume in 1 second) AUC(6-12h) response is defined as change from the baseline value. AUC(6-12h) will be calculated as the area under the curve from 6 to 12 hours on the various test days using the trapezoidal rule, divided by the full duration (6 hours) to report in litres. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on ANCOVA with terms for baseline, treatment, and centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF (Unsupervised) AUC(6-12h) Response [L/Min] After First Administration and 1,2 and 4 Weeks of Treatment</measure>
    <time_frame>6 h, 9 h and 12 h after inhalation at baseline and after 1 week, 2 weeks and 4 weeks</time_frame>
    <description>PEF (peak expiratory flow rate L/min) AUC(6-12h) response is defined as change from the baseline value. AUC(6-12h) will be calculated as the area under the curve from 6 to 12 hours on the various test days using the trapezoidal rule, divided by the full duration (6 hours) to report in litres/min. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on ANCOVA with terms for baseline, treatment, and centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean Pre-dose Morning PEF [L/Min]</measure>
    <time_frame>Throughout the 4 week treatment period</time_frame>
    <description>The patient will record twice daily peak flow measurements using an Asthma Monitor®Am2+ (AM2+) device. Morning measurements will be performed immediately upon arising after the patient has cleared out mucus, prior to administration of trial and/or rescue medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean Evening PEF [L/Min]</measure>
    <time_frame>Throughout the 4 weeks treatment period</time_frame>
    <description>The patient will record twice daily peak flow measurements using an AM2+ device. The evening measurement will be performed at bedtime.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly Mean Number of Occasions of Rescue Therapy Used Per Day</measure>
    <time_frame>Throughout the 4 weeks treatment period</time_frame>
    <description>The means are adjusted, Based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Evaluation</measure>
    <time_frame>1 week, 2 weeks and 4 weeks</time_frame>
    <description>Measured a 8-point scale, from 1 (poor) to 8 (excellent), as judged by the physician, over 4 weeks of treatment.
The physician made a global evaluation at the end of the Baseline Period (Test Day 1) and at each visit thereafter. These assessments were made prior to pulmonary function testing and reflected the physician's opinion of the patient's overall clinical condition. This evaluation was based on the need for concomitant medication, number and severity of COPD exacerbations since the last visit, severity of cough, ability to exercise, amount of wheezing, and other relevant clinical observations.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Rating</measure>
    <time_frame>4 weeks</time_frame>
    <description>Patient's Global Rating at the end of the 4 week treatment period.
Patients rated their health (respiratory condition) at Day 29 (compared to the day before they commenced treatment with study medication) on a 7-point scale as &quot;very much better (1), much better (2), a little better (3), no change (4), a little worse (5), much worse (6), or very much worse (7)&quot;. The assessment was made prior to pulmonary function testing and all other study procedures. The Patient's Global Rating was also completed before the Physician's Global Evaluation.
The means are adjusted, based on an ANCOVA with terms for treatment, centre (centre random, treatment effect fixed).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Anormalities (Laboratory Data); Marked Changes From Baseline for Vital Signs, Notable Change in ECG and New Onset of ECG Abnormalities</measure>
    <time_frame>From first dose up to 21 days after last dose of study medication.</time_frame>
    <description>Possible clinically significant anormalities (laboratory data); marked changes from baseline for vital signs, notable change in ECG and new onset of ECG abnormalities. New abnormal findings or worsening of baseline conditions were reported as Adverse Events (AEs).
All AEs with an onset after the first dose of study medication up to 21 days after the last dose of study medication were to have been assigned to the Treatment Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss Olodaterol [pg/mL]</measure>
    <time_frame>Pre-dose, 5 min, 10 min, 20 min, 40 min, 1 h, 3 h, and 6 h after the last dose.</time_frame>
    <description>Maximum measured concentration of Olodaterol in plasma at steady state (Cmax,ss) after 4 weeks of treatment.
No results displayed for Tiotropium+Olodaterol 5/2 μg because there were zero total participants analyzed for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss Olodaterol [h]</measure>
    <time_frame>Pre-dose, 5 min, 10 min, 20 min, 40 min, 1 h, 3 h, and 6 h after the last dose.</time_frame>
    <description>Time from last dosing to maximum concentration of Olodaterol in plasma at steady state (tmax,ss) after 4 weeks treatment.
No results displayed for Tiotropium+Olodaterol 5/2 μg because there were zero total participants analyzed for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-1h,ss) Olodaterol [pg*h/mL]</measure>
    <time_frame>Pre-dose, 5 min, 10 min, 20 min, 40 min, 1 h, 3 h, and 6 h after the last dose.</time_frame>
    <description>Area under the concentration-time curve of Olodaterol in plasma at steady state (AUC(0-1h,ss)) from 0 to 1 hour post dosing after 4 weeks of treatment.
No results displayed for Tiotropium+Olodaterol 5/2 μg because there were zero total participants analyzed for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss Tiotropium [pg/mL]</measure>
    <time_frame>Pre-dose, 5 min, 10 min, 20 min, 40 min, 1 h, 3 h, and 6 h after the last dose.</time_frame>
    <description>Maximum measured concentration of Tiotropium in plasma at steady state (Cmax,ss) after 4 weeks treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss Tiotropium [h]</measure>
    <time_frame>Pre-dose, 5 min, 10 min, 20 min, 40 min, 1 h, 3 h, and 6 h after the last dose.</time_frame>
    <description>Time from last dosing to maximum concentration of Tiotropium in plasma at steady state (tmax,ss) after 4 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-3h,ss) Tiotropium [pg*h/mL]</measure>
    <time_frame>Pre-dose, 5 min, 10 min, 20 min, 40 min, 1 h, 3 h, and 6 h after the last dose.</time_frame>
    <description>Area under the concentration-time curve of Tiotropium at steady state (AUC(0-3h,ss)) from 0 to 3 hours post dosing after 4 weeks of treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>BI 1744 CL low dose/tiotropium bromide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 1744 CL low dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI1744CL medium dose/tiotropium bromide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 1744 CL medium dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1744 CL high dose/tiotropium bromide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 1744 CL high dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tiotropium bromide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tiotropium bromide; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1744 CL/tiotropium bromide fixed dose combination</intervention_name>
    <description>BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation</description>
    <arm_group_label>BI 1744 CL low dose/tiotropium bromide</arm_group_label>
    <arm_group_label>BI1744CL medium dose/tiotropium bromide</arm_group_label>
    <arm_group_label>BI 1744 CL high dose/tiotropium bromide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium bromide</intervention_name>
    <description>tiotropium bromide; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation</description>
    <arm_group_label>tiotropium bromide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respimat® Inhaler</intervention_name>
    <arm_group_label>BI 1744 CL low dose/tiotropium bromide</arm_group_label>
    <arm_group_label>BI1744CL medium dose/tiotropium bromide</arm_group_label>
    <arm_group_label>BI 1744 CL high dose/tiotropium bromide</arm_group_label>
    <arm_group_label>tiotropium bromide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All patients must sign an informed consent consistent with ICH-GCP guidelines prior to
             participation in the trial, which includes medication washout and restrictions

          2. All patients must have a diagnosis of chronic obstructive pulmonary disease and must
             meet the following spirometric criteria:

             Patients must have relatively stable airway obstruction with a post-bronchodilator
             FEV1 greater or equal 30% of predicted normal and &lt;80% of predicted normal and a
             post-bronchodilator FEV1 / FVC &lt;70% at Visit 1

          3. Male or female patients, 40 years of age or older

          4. Patients must be current or ex-smokers with a smoking history of more than 10 pack
             years

          5. Patients must be able to perform technically acceptable pulmonary function tests and
             PEF measurements, and must be able to maintain records (Patient Daily e-Diary) during
             the study period as required in the protocol

          6. Patients must be able to inhale medication in a competent manner from the Respimat
             inhaler and from a metered dose inhaler (MDI).

        Further inclusion criteria apply

        Exclusion Criteria:

          1. Patients with a significant disease other than COPD

          2. Patients with clinically relevant abnormal baseline haematology, blood chemistry, or
             urinalysis;

          3. Patients with a history of asthma or a total blood eosinophil count &gt;= 600/mm3.

          4. Patients with any of the following conditions:a diagnosis of thyrotoxicosis, a
             diagnosis of paroxysmal tachycardia (&gt;100 beats per minute), a marked baseline
             prolongation of QT/QTc interval (e.g. repeated demonstration of a QTcF* interval &gt; 450
             ms), a history of additional risk factors for Torsade de Pointes (TdP) (e.g. heart
             failure, hypokalemia, family history of Long QT Syndrome)

          5. Patients with any of the following conditions:a history of myocardial infarction
             within 1 year of screening visit (Visit 1), a diagnosis of clinically relevant cardiac
             arrhythmia, known active tuberculosis, a malignancy for which patient has undergone
             resection, radiation therapy or chemotherapy within last five years, a history of
             life-threatening pulmonary obstruction, a history of cystic fibrosis, clinically
             evident bronchiectasis, a history of significant alcohol or drug abuse

          6. Patients who have undergone thoracotomy with pulmonary resection

          7. Patients who regularly use daytime oxygen therapy for more than one hour per day and
             in the investigator's opinion will be unable to abstain from the use of oxygen therapy
             during clinic visits.

          8. Pregnant or nursing women

          9. Women of childbearing potential not using two effective method of birth control (one
             barrier and one non-barrier). Female patients will be considered to be of childbearing
             potential unless surgically sterilised by hysterectomy or bilateral tubal ligation, or
             post-menopausal for at least two years

         10. Patients who have previously been randomized in this study or are currently
             participating in another study

         11. Patients who are unable to comply with pulmonary medication restrictions prior to
             randomization

         12. Patients who have taken an investigational drug within one month or six half lives
             (whichever is greater) prior to Screening Visit

        Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1237.4.0118 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0115 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0117 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0120 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0119 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Charles</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0114 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0123 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0122 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0116 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0121 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0208 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.0207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.4903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.4907 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Erfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.4902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gauting</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.4908 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.4906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neuruppin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.4904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rüdersdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.4.4901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Weinheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2008</study_first_submitted>
  <study_first_submitted_qc>June 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2008</study_first_posted>
  <results_first_submitted>June 19, 2015</results_first_submitted>
  <results_first_submitted_qc>July 20, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 13, 2015</results_first_posted>
  <disposition_first_submitted>March 28, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>March 28, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 25, 2014</disposition_first_posted>
  <last_update_submitted>July 20, 2015</last_update_submitted>
  <last_update_submitted_qc>July 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Olodaterol</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A randomised, double-blind, parallel group study. Each patient received their randomised treatment for 28 days.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>5 µg Tiotropium</title>
          <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="P2">
          <title>Tiotropium+Olodaterol 5/2 μg</title>
          <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="P3">
          <title>Tiotropium+Olodaterol 5/5 μg</title>
          <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="P4">
          <title>Tiotropium+Olodaterol 5/10 μg</title>
          <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="93"/>
                <participants group_id="P4" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="90"/>
                <participants group_id="P4" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other not stated above</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set (TS). The TS included all randomized patients who received at least 1 dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>5 µg Tiotropium</title>
          <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="B2">
          <title>Tiotropium+Olodaterol 5/2 μg</title>
          <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="B3">
          <title>Tiotropium+Olodaterol 5/5 μg</title>
          <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="B4">
          <title>Tiotropium+Olodaterol 5/10 μg</title>
          <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
            <count group_id="B2" value="89"/>
            <count group_id="B3" value="93"/>
            <count group_id="B4" value="88"/>
            <count group_id="B5" value="360"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.87" spread="8.50"/>
                    <measurement group_id="B2" value="64.44" spread="9.18"/>
                    <measurement group_id="B3" value="64.19" spread="9.59"/>
                    <measurement group_id="B4" value="62.66" spread="8.86"/>
                    <measurement group_id="B5" value="63.30" spread="9.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Trough FEV1 Response [L] After 4 Weeks of Treatment</title>
        <description>Trough FEV1 (Forced expiratory volume in 1 second) was defined as the mean of the two FEV1 values (performed at 1 h and 10 min prior to study medication inhalation) at the end of the dosing interval, 24 hours post-drug administration. Trough FEV1 response was defined as the change from baseline in trough FEV1. Baseline FEV1 was defined as the mean of the 2 pre-treatment FEV1 values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on ANCOVA with terms for baseline, treatment, and centre (centre random, all other effects fixed).</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>Full Analysis Set (FAS). The FAS consisted of all patients who received at least 1 dose of study medication and had baseline data (pre-treatment at the end of the 2-week baseline) for at least 1 efficacy endpoint. For this trial all randomized and treated patients were included in the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response [L] After 4 Weeks of Treatment</title>
          <description>Trough FEV1 (Forced expiratory volume in 1 second) was defined as the mean of the two FEV1 values (performed at 1 h and 10 min prior to study medication inhalation) at the end of the dosing interval, 24 hours post-drug administration. Trough FEV1 response was defined as the change from baseline in trough FEV1. Baseline FEV1 was defined as the mean of the 2 pre-treatment FEV1 values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on ANCOVA with terms for baseline, treatment, and centre (centre random, all other effects fixed).</description>
          <population>Full Analysis Set (FAS). The FAS consisted of all patients who received at least 1 dose of study medication and had baseline data (pre-treatment at the end of the 2-week baseline) for at least 1 efficacy endpoint. For this trial all randomized and treated patients were included in the FAS.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.110" spread="0.021"/>
                    <measurement group_id="O2" value="0.134" spread="0.021"/>
                    <measurement group_id="O3" value="0.143" spread="0.020"/>
                    <measurement group_id="O4" value="0.168" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3791</p_value>
            <p_value_desc>Type I error was controlled by a closed stepwise procedure.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, and centre (centre random, all other effects fixed).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.024</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.029</ci_lower_limit>
            <ci_upper_limit>0.076</ci_upper_limit>
            <estimate_desc>2 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2133</p_value>
            <p_value_desc>Type I error was controlled by a closed stepwise procedure.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, and centre (centre random, all other effects fixed).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.033</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.019</ci_lower_limit>
            <ci_upper_limit>0.085</ci_upper_limit>
            <estimate_desc>5 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0337</p_value>
            <p_value_desc>Type I error was controlled by a closed stepwise procedure.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, and centre (centre random, all other effects fixed).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.057</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.004</ci_lower_limit>
            <ci_upper_limit>0.110</ci_upper_limit>
            <estimate_desc>10 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response [L] After 1 and 2 Weeks of Treatment.</title>
        <description>Trough FEV1 (forced expiratory volume in 1 second) was defined as the mean of the 2 FEV1 values (performed at 1 h and 10 min prior to study medication inhalation) at the end of the dosing interval, 24 hours post-drug administration. Trough FEV1 response was defined as the change from baseline in trough FEV1. Baseline FEV1 was defined as the mean of the 2 pre-treatment FEV1 values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 15.</description>
        <time_frame>Baseline, 1 week and 2 weeks</time_frame>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response [L] After 1 and 2 Weeks of Treatment.</title>
          <description>Trough FEV1 (forced expiratory volume in 1 second) was defined as the mean of the 2 FEV1 values (performed at 1 h and 10 min prior to study medication inhalation) at the end of the dosing interval, 24 hours post-drug administration. Trough FEV1 response was defined as the change from baseline in trough FEV1. Baseline FEV1 was defined as the mean of the 2 pre-treatment FEV1 values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 15.</description>
          <population>Full Analysis Set.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.093" spread="0.020"/>
                    <measurement group_id="O2" value="0.149" spread="0.020"/>
                    <measurement group_id="O3" value="0.154" spread="0.019"/>
                    <measurement group_id="O4" value="0.166" spread="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.099" spread="0.020"/>
                    <measurement group_id="O2" value="0.141" spread="0.020"/>
                    <measurement group_id="O3" value="0.159" spread="0.020"/>
                    <measurement group_id="O4" value="0.154" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1163</p_value>
            <p_value_desc>Type I error was controlled by a closed stepwise procedure.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, and centre (centre random, all other effects fixed).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.042</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.010</ci_lower_limit>
            <ci_upper_limit>0.093</ci_upper_limit>
            <estimate_desc>2 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0224</p_value>
            <p_value_desc>Type I error was controlled by a closed stepwise procedure.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, and centre (centre random, all other effects fixed).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.060</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.009</ci_lower_limit>
            <ci_upper_limit>0.111</ci_upper_limit>
            <estimate_desc>5 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0380</p_value>
            <p_value_desc>Type I error was controlled by a closed stepwise procedure.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, and centre (centre random, all other effects fixed).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.055</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.003</ci_lower_limit>
            <ci_upper_limit>0.107</ci_upper_limit>
            <estimate_desc>10 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response [L] After 1, 2 and 4 Weeks of Treatment</title>
        <description>Trough FVC (forced vital capacity) was defined as the mean of the 2 FVC values (performed at 1 h and 10 min prior to study medication inhalation) at the end of the dosing interval, 24 hours post-drug administration. Trough FVC response was defined as the change from baseline in trough FVC. Baseline FVC was defined as the mean of the 2 pre-treatment FVC values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
        <time_frame>Baseline, 1 week, 2 weeks and 4 weeks</time_frame>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response [L] After 1, 2 and 4 Weeks of Treatment</title>
          <description>Trough FVC (forced vital capacity) was defined as the mean of the 2 FVC values (performed at 1 h and 10 min prior to study medication inhalation) at the end of the dosing interval, 24 hours post-drug administration. Trough FVC response was defined as the change from baseline in trough FVC. Baseline FVC was defined as the mean of the 2 pre-treatment FVC values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
          <population>Full Analysis Set.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.156" spread="0.033"/>
                    <measurement group_id="O2" value="0.215" spread="0.033"/>
                    <measurement group_id="O3" value="0.265" spread="0.032"/>
                    <measurement group_id="O4" value="0.275" spread="0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.171" spread="0.034"/>
                    <measurement group_id="O2" value="0.196" spread="0.034"/>
                    <measurement group_id="O3" value="0.280" spread="0.033"/>
                    <measurement group_id="O4" value="0.285" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.189" spread="0.036"/>
                    <measurement group_id="O2" value="0.191" spread="0.036"/>
                    <measurement group_id="O3" value="0.288" spread="0.036"/>
                    <measurement group_id="O4" value="0.306" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9573</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.002</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.047</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.089</ci_lower_limit>
            <ci_upper_limit>0.094</ci_upper_limit>
            <estimate_desc>2 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0321</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.099</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.046</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.009</ci_lower_limit>
            <ci_upper_limit>0.189</ci_upper_limit>
            <estimate_desc>5 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0125</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.117</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.047</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.025</ci_lower_limit>
            <ci_upper_limit>0.209</ci_upper_limit>
            <estimate_desc>10 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC(0-3h) Response [L] After First Administration and After 1, 2 and 4 Weeks of Treatment</title>
        <description>Response is defined as change from the baseline value. AUC(0-3h) (area under the curve) was calculated as the area under the curve from 0 to 3 hours on the various test days using the trapezoidal rule, divided by the full duration (3 hours) to report in litres. Baseline FEV1 was defined as the mean of the 2 pre-treatment FEV1 values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
        <time_frame>1 h and 10 min prior to inhalation and 5 min (only for week 1 and 2), 30 min, 1 h, 2 h and 3 h after inhalation at baseline and after 1, 2 and 4 weeks</time_frame>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC(0-3h) Response [L] After First Administration and After 1, 2 and 4 Weeks of Treatment</title>
          <description>Response is defined as change from the baseline value. AUC(0-3h) (area under the curve) was calculated as the area under the curve from 0 to 3 hours on the various test days using the trapezoidal rule, divided by the full duration (3 hours) to report in litres. Baseline FEV1 was defined as the mean of the 2 pre-treatment FEV1 values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
          <population>Full Analysis Set.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.161" spread="0.016"/>
                    <measurement group_id="O2" value="0.201" spread="0.016"/>
                    <measurement group_id="O3" value="0.229" spread="0.016"/>
                    <measurement group_id="O4" value="0.225" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.204" spread="0.024"/>
                    <measurement group_id="O2" value="0.289" spread="0.024"/>
                    <measurement group_id="O3" value="0.302" spread="0.023"/>
                    <measurement group_id="O4" value="0.315" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.201" spread="0.024"/>
                    <measurement group_id="O2" value="0.288" spread="0.024"/>
                    <measurement group_id="O3" value="0.305" spread="0.024"/>
                    <measurement group_id="O4" value="0.309" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.191" spread="0.023"/>
                    <measurement group_id="O2" value="0.276" spread="0.023"/>
                    <measurement group_id="O3" value="0.270" spread="0.022"/>
                    <measurement group_id="O4" value="0.316" spread="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0052</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.085</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.030</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.026</ci_lower_limit>
            <ci_upper_limit>0.145</ci_upper_limit>
            <estimate_desc>2 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0086</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.079</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.030</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.020</ci_lower_limit>
            <ci_upper_limit>0.138</ci_upper_limit>
            <estimate_desc>5 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.125</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.030</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.066</ci_lower_limit>
            <ci_upper_limit>0.185</ci_upper_limit>
            <estimate_desc>10 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC(0-3h) Response [L] After First Administration and After 1, 2 and 4 Weeks of Treatment.</title>
        <description>FVC (forced vital capacity) AUC(0-3h) response is defined as change from the baseline value. AUC(0-3h) was calculated as the area under the curve from 0 to 3 hours on the various test days using the trapezoidal rule, divided by the full duration (3 hours) to report in litres. Baseline FVC was defined as the mean of the 2 pre-treatment FVC values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
        <time_frame>1 h and 10 min prior to inhalation and 5 min (only for week 1 and 2), 30 min, 1 h, 2 h and 3 h after inhalation at baseline and after 1, 2 and 4 weeks</time_frame>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC(0-3h) Response [L] After First Administration and After 1, 2 and 4 Weeks of Treatment.</title>
          <description>FVC (forced vital capacity) AUC(0-3h) response is defined as change from the baseline value. AUC(0-3h) was calculated as the area under the curve from 0 to 3 hours on the various test days using the trapezoidal rule, divided by the full duration (3 hours) to report in litres. Baseline FVC was defined as the mean of the 2 pre-treatment FVC values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
          <population>Full Analysis Set.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.268" spread="0.032"/>
                    <measurement group_id="O2" value="0.331" spread="0.032"/>
                    <measurement group_id="O3" value="0.413" spread="0.031"/>
                    <measurement group_id="O4" value="0.410" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.310" spread="0.042"/>
                    <measurement group_id="O2" value="0.441" spread="0.042"/>
                    <measurement group_id="O3" value="0.493" spread="0.041"/>
                    <measurement group_id="O4" value="0.537" spread="0.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.327" spread="0.044"/>
                    <measurement group_id="O2" value="0.437" spread="0.044"/>
                    <measurement group_id="O3" value="0.513" spread="0.043"/>
                    <measurement group_id="O4" value="0.554" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.308" spread="0.043"/>
                    <measurement group_id="O2" value="0.424" spread="0.043"/>
                    <measurement group_id="O3" value="0.492" spread="0.043"/>
                    <measurement group_id="O4" value="0.547" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0384</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.116</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.006</ci_lower_limit>
            <ci_upper_limit>0.225</ci_upper_limit>
            <estimate_desc>2 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.184</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.055</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.076</ci_lower_limit>
            <ci_upper_limit>0.292</ci_upper_limit>
            <estimate_desc>5 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.239</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.130</ci_lower_limit>
            <ci_upper_limit>0.349</ci_upper_limit>
            <estimate_desc>10 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEF AUC(0-3h) Response [L/Min] After First Administration and After 1, 2 and 4 Weeks of Treatment.</title>
        <description>PEF (peak expiratory flow rate L/min) AUC(0-3h) response is defined as change from the baseline value. AUC(0-3h) will be calculated as the area under the curve from 0 to 3 hours on the various test days using the trapezoidal rule, divided by the full duration (3 hours) to report in litres/min. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
        <time_frame>1 h and 10 min prior to inhalation and 5 min (only for week 1 and 2), 30 min, 1 h, 2 h and 3 h after inhalation at baseline and after 1, 2 and 4 weeks</time_frame>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>PEF AUC(0-3h) Response [L/Min] After First Administration and After 1, 2 and 4 Weeks of Treatment.</title>
          <description>PEF (peak expiratory flow rate L/min) AUC(0-3h) response is defined as change from the baseline value. AUC(0-3h) will be calculated as the area under the curve from 0 to 3 hours on the various test days using the trapezoidal rule, divided by the full duration (3 hours) to report in litres/min. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
          <population>Full Analysis Set.</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.973" spread="3.596"/>
                    <measurement group_id="O2" value="35.738" spread="3.614"/>
                    <measurement group_id="O3" value="35.350" spread="3.533"/>
                    <measurement group_id="O4" value="40.027" spread="3.646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.701" spread="4.966"/>
                    <measurement group_id="O2" value="52.816" spread="4.973"/>
                    <measurement group_id="O3" value="49.722" spread="4.875"/>
                    <measurement group_id="O4" value="53.448" spread="5.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.108" spread="5.115"/>
                    <measurement group_id="O2" value="54.527" spread="5.130"/>
                    <measurement group_id="O3" value="53.829" spread="5.022"/>
                    <measurement group_id="O4" value="54.289" spread="5.180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.734" spread="4.889"/>
                    <measurement group_id="O2" value="52.091" spread="4.912"/>
                    <measurement group_id="O3" value="48.503" spread="4.802"/>
                    <measurement group_id="O4" value="56.688" spread="4.956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>22.357</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.760</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.057</ci_lower_limit>
            <ci_upper_limit>35.657</ci_upper_limit>
            <estimate_desc>2 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0053</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>18.769</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.687</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.613</ci_lower_limit>
            <ci_upper_limit>31.924</ci_upper_limit>
            <estimate_desc>5 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>26.954</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.805</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.565</ci_lower_limit>
            <ci_upper_limit>40.343</ci_upper_limit>
            <estimate_desc>10 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC(0-6h) Response [L] After 4 Weeks of Treatment</title>
        <description>FEV1 (forced expiratory volume in 1 second) AUC(0-6h) response is defined as change from the baseline value. AUC(0-6h) will be calculated as the area under the curve from 0 to 6 hours on test day 29 using the trapezoidal rule, divided by the full duration (6 hours) to report in litres. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on ANCOVA with terms for baseline, treatment, and centre (centre random, all other effects fixed).</description>
        <time_frame>1 h and 10 min prior to inhalation at baseline and after 4 weeks and 30 min, 1 h, 2 h, 3 h, 4 h, 5 h and 6h after inhalation at baseline and after 4 weeks (Day 29)</time_frame>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC(0-6h) Response [L] After 4 Weeks of Treatment</title>
          <description>FEV1 (forced expiratory volume in 1 second) AUC(0-6h) response is defined as change from the baseline value. AUC(0-6h) will be calculated as the area under the curve from 0 to 6 hours on test day 29 using the trapezoidal rule, divided by the full duration (6 hours) to report in litres. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on ANCOVA with terms for baseline, treatment, and centre (centre random, all other effects fixed).</description>
          <population>Full Analysis Set.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.194" spread="0.023"/>
                    <measurement group_id="O2" value="0.282" spread="0.023"/>
                    <measurement group_id="O3" value="0.280" spread="0.023"/>
                    <measurement group_id="O4" value="0.322" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0048</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, and centre (centre random, all other effects fixed).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.088</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.031</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.027</ci_lower_limit>
            <ci_upper_limit>0.149</ci_upper_limit>
            <estimate_desc>2 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0056</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, and centre (centre random, all other effects fixed).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.086</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.031</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.025</ci_lower_limit>
            <ci_upper_limit>0.146</ci_upper_limit>
            <estimate_desc>5 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, and centre (centre random, all other effects fixed).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.128</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.031</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.066</ci_lower_limit>
            <ci_upper_limit>0.189</ci_upper_limit>
            <estimate_desc>10 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC(0-6h) Response [L] After 4 Weeks of Treatment</title>
        <description>FVC (forced vital capacity) AUC(0-6h) response is defined as change from the baseline value. AUC(0-6h) will be calculated as the area under the curve from 0 to 6 hours on test day 29 using the trapezoidal rule, divided by the full duration (6 hours) to report in litres. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).</description>
        <time_frame>1 h and 10 min prior to inhalation at baseline and after 4 weeks and 30 min, 1 h, 2 h, 3 h, 4 h, 5 h and 6h after inhalation at baseline and after 4 weeks (Day 29)</time_frame>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC(0-6h) Response [L] After 4 Weeks of Treatment</title>
          <description>FVC (forced vital capacity) AUC(0-6h) response is defined as change from the baseline value. AUC(0-6h) will be calculated as the area under the curve from 0 to 6 hours on test day 29 using the trapezoidal rule, divided by the full duration (6 hours) to report in litres. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).</description>
          <population>Full Analysis Set.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.309" spread="0.044"/>
                    <measurement group_id="O2" value="0.429" spread="0.044"/>
                    <measurement group_id="O3" value="0.492" spread="0.043"/>
                    <measurement group_id="O4" value="0.547" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0332</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.120</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.010</ci_lower_limit>
            <ci_upper_limit>0.230</ci_upper_limit>
            <estimate_desc>2 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.183</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.055</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.074</ci_lower_limit>
            <ci_upper_limit>0.292</ci_upper_limit>
            <estimate_desc>5 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.238</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.128</ci_lower_limit>
            <ci_upper_limit>0.349</ci_upper_limit>
            <estimate_desc>10 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEF AUC(0-6h) Response [L] After 4 Weeks of Treatment</title>
        <description>PEF (peak expiratory flow rate L/min) AUC(0-6h) response is defined as change from the baseline value. AUC(0-6h) will be calculated as the area under the curve from 0 to 6 hours on test day 29 using the trapezoidal rule, divided by the full duration (6 hours) to report in litres. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).</description>
        <time_frame>1 h and 10 min prior to inhalation at baseline and after 4 weeks and 30 min, 1 h, 2 h, 3 h, 4 h, 5 h and 6h after inhalation at baseline and after 4 weeks (Day 29)</time_frame>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>PEF AUC(0-6h) Response [L] After 4 Weeks of Treatment</title>
          <description>PEF (peak expiratory flow rate L/min) AUC(0-6h) response is defined as change from the baseline value. AUC(0-6h) will be calculated as the area under the curve from 0 to 6 hours on test day 29 using the trapezoidal rule, divided by the full duration (6 hours) to report in litres. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).</description>
          <population>Full Analysis Set.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.576" spread="4.933"/>
                    <measurement group_id="O2" value="53.443" spread="4.956"/>
                    <measurement group_id="O3" value="50.319" spread="4.845"/>
                    <measurement group_id="O4" value="58.368" spread="5.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>22.867</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.813</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.462</ci_lower_limit>
            <ci_upper_limit>36.272</ci_upper_limit>
            <estimate_desc>2 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0036</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>19.743</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.739</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.484</ci_lower_limit>
            <ci_upper_limit>33.002</ci_upper_limit>
            <estimate_desc>5 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>27.793</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.859</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.298</ci_lower_limit>
            <ci_upper_limit>41.287</ci_upper_limit>
            <estimate_desc>10 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Peak(0-3h) Response [L] After First Administration and After 1, 2 and 4 Weeks of Treatment</title>
        <description>FEV1 (forced expiratory volume in 1 second) peak(0-3h) is the maximum post-dose value during the first 3 hours after first administration and after 1, 2 and 4 weeks of treatment. Response is defined as change from the baseline value. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
        <time_frame>5 min (only for week 1 and 2), 30 min, 1 h, 2 h and 3 h after inhalation at baseline and after 1 week, 2 weeks and 4 weeks</time_frame>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Peak(0-3h) Response [L] After First Administration and After 1, 2 and 4 Weeks of Treatment</title>
          <description>FEV1 (forced expiratory volume in 1 second) peak(0-3h) is the maximum post-dose value during the first 3 hours after first administration and after 1, 2 and 4 weeks of treatment. Response is defined as change from the baseline value. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
          <population>Full Analysis Set.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.249" spread="0.019"/>
                    <measurement group_id="O2" value="0.284" spread="0.019"/>
                    <measurement group_id="O3" value="0.311" spread="0.019"/>
                    <measurement group_id="O4" value="0.321" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.276" spread="0.025"/>
                    <measurement group_id="O2" value="0.359" spread="0.025"/>
                    <measurement group_id="O3" value="0.378" spread="0.024"/>
                    <measurement group_id="O4" value="0.397" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.276" spread="0.026"/>
                    <measurement group_id="O2" value="0.361" spread="0.026"/>
                    <measurement group_id="O3" value="0.391" spread="0.026"/>
                    <measurement group_id="O4" value="0.386" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.266" spread="0.024"/>
                    <measurement group_id="O2" value="0.353" spread="0.024"/>
                    <measurement group_id="O3" value="0.348" spread="0.024"/>
                    <measurement group_id="O4" value="0.410" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0079</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.088</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.033</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.023</ci_lower_limit>
            <ci_upper_limit>0.152</ci_upper_limit>
            <estimate_desc>2 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0120</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.082</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.032</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.018</ci_lower_limit>
            <ci_upper_limit>0.146</ci_upper_limit>
            <estimate_desc>5 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.144</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.033</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.080</ci_lower_limit>
            <ci_upper_limit>0.209</ci_upper_limit>
            <estimate_desc>10 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Peak(0-3h) Response [L] After First Administration and After 1, 2 and 4 Weeks of Treatment</title>
        <description>FVC (forced vital capacity) peak(0-3h) is the maximum post-dose value during the first 3 hours after first administration and after 1, 2 and 4 weeks of treatment. Response is defined as change from the baseline value. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
        <time_frame>5 min (only for week 1 and 2), 30 min, 1 h, 2 h and 3 h after inhalation at baseline and after 1 week, 2 weeks and 4 weeks</time_frame>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Peak(0-3h) Response [L] After First Administration and After 1, 2 and 4 Weeks of Treatment</title>
          <description>FVC (forced vital capacity) peak(0-3h) is the maximum post-dose value during the first 3 hours after first administration and after 1, 2 and 4 weeks of treatment. Response is defined as change from the baseline value. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
          <population>Full Analysis Set.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.428" spread="0.037"/>
                    <measurement group_id="O2" value="0.476" spread="0.037"/>
                    <measurement group_id="O3" value="0.576" spread="0.036"/>
                    <measurement group_id="O4" value="0.583" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.437" spread="0.043"/>
                    <measurement group_id="O2" value="0.560" spread="0.043"/>
                    <measurement group_id="O3" value="0.615" spread="0.042"/>
                    <measurement group_id="O4" value="0.690" spread="0.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.465" spread="0.047"/>
                    <measurement group_id="O2" value="0.586" spread="0.047"/>
                    <measurement group_id="O3" value="0.648" spread="0.046"/>
                    <measurement group_id="O4" value="0.697" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.431" spread="0.045"/>
                    <measurement group_id="O2" value="0.562" spread="0.045"/>
                    <measurement group_id="O3" value="0.634" spread="0.044"/>
                    <measurement group_id="O4" value="0.696" spread="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0296</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.131</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.060</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.013</ci_lower_limit>
            <ci_upper_limit>0.249</ci_upper_limit>
            <estimate_desc>2 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.204</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.059</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.087</ci_lower_limit>
            <ci_upper_limit>0.320</ci_upper_limit>
            <estimate_desc>5 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.265</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.060</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.147</ci_lower_limit>
            <ci_upper_limit>0.383</ci_upper_limit>
            <estimate_desc>10 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEF Peak(0-3h) Response [L] After First Administration and After 1, 2 and 4 Weeks of Treatment</title>
        <description>PEF (peak expiratory flow rate L/min) peak(0-3h) is the maximum post-dose value during the first 3 hours after first administration and after 1, 2 and 4 weeks of treatment. Response is defined as change from the baseline value. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
        <time_frame>5 min (only for week 1 and 2), 30 min, 1 h, 2 h and 3 h after inhalation at baseline and after 1 week, 2 weeks and 4 weeks</time_frame>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>PEF Peak(0-3h) Response [L] After First Administration and After 1, 2 and 4 Weeks of Treatment</title>
          <description>PEF (peak expiratory flow rate L/min) peak(0-3h) is the maximum post-dose value during the first 3 hours after first administration and after 1, 2 and 4 weeks of treatment. Response is defined as change from the baseline value. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
          <population>Full Analysis Set.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.051" spread="4.445"/>
                    <measurement group_id="O2" value="53.801" spread="4.474"/>
                    <measurement group_id="O3" value="53.853" spread="4.370"/>
                    <measurement group_id="O4" value="62.360" spread="4.510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.819" spread="5.213"/>
                    <measurement group_id="O2" value="69.792" spread="5.227"/>
                    <measurement group_id="O3" value="69.254" spread="5.118"/>
                    <measurement group_id="O4" value="73.828" spread="5.279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.129" spread="6.897"/>
                    <measurement group_id="O2" value="79.890" spread="6.930"/>
                    <measurement group_id="O3" value="71.916" spread="6.775"/>
                    <measurement group_id="O4" value="73.886" spread="6.992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.104" spread="5.088"/>
                    <measurement group_id="O2" value="70.519" spread="5.114"/>
                    <measurement group_id="O3" value="65.800" spread="4.999"/>
                    <measurement group_id="O4" value="76.461" spread="5.159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>23.414</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.057</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.529</ci_lower_limit>
            <ci_upper_limit>37.300</ci_upper_limit>
            <estimate_desc>2 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0078</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>18.695</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.981</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.961</ci_lower_limit>
            <ci_upper_limit>32.430</ci_upper_limit>
            <estimate_desc>5 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>29.357</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.105</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.379</ci_lower_limit>
            <ci_upper_limit>43.335</ci_upper_limit>
            <estimate_desc>10 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 and PEF (Unsupervised) AUC(0-6h) Response [L] After First Administration and After 1, 2 and 4 Weeks of Treatment</title>
        <description>AUC(0-6h) for FEV1, and PEF (unsupervised) were not studied because the pertinent information from the unsupervised pulmonary function tests was for the time interval from 9 to 12 hours post-dosing.</description>
        <time_frame>After first administration, 1 week, 2 weeks and 4 weeks</time_frame>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 and PEF (Unsupervised) AUC(0-6h) Response [L] After First Administration and After 1, 2 and 4 Weeks of Treatment</title>
          <description>AUC(0-6h) for FEV1, and PEF (unsupervised) were not studied because the pertinent information from the unsupervised pulmonary function tests was for the time interval from 9 to 12 hours post-dosing.</description>
          <population>Full Analysis Set.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 (Unsupervised) AUC(6-12h) Response [L] After First Administration and 1,2 and 4 Weeks of Treatment</title>
        <description>FEV1 (forced expiratory volume in 1 second) AUC(6-12h) response is defined as change from the baseline value. AUC(6-12h) will be calculated as the area under the curve from 6 to 12 hours on the various test days using the trapezoidal rule, divided by the full duration (6 hours) to report in litres. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on ANCOVA with terms for baseline, treatment, and centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
        <time_frame>6 h, 9 h and 12 h after inhalation at baseline and after 1 week, 2 weeks and 4 weeks</time_frame>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 (Unsupervised) AUC(6-12h) Response [L] After First Administration and 1,2 and 4 Weeks of Treatment</title>
          <description>FEV1 (forced expiratory volume in 1 second) AUC(6-12h) response is defined as change from the baseline value. AUC(6-12h) will be calculated as the area under the curve from 6 to 12 hours on the various test days using the trapezoidal rule, divided by the full duration (6 hours) to report in litres. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on ANCOVA with terms for baseline, treatment, and centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
          <population>Full Analysis Set.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.143" spread="0.031"/>
                    <measurement group_id="O2" value="0.181" spread="0.031"/>
                    <measurement group_id="O3" value="0.209" spread="0.031"/>
                    <measurement group_id="O4" value="0.175" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.169" spread="0.035"/>
                    <measurement group_id="O2" value="0.203" spread="0.035"/>
                    <measurement group_id="O3" value="0.219" spread="0.035"/>
                    <measurement group_id="O4" value="0.172" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.142" spread="0.038"/>
                    <measurement group_id="O2" value="0.197" spread="0.038"/>
                    <measurement group_id="O3" value="0.205" spread="0.038"/>
                    <measurement group_id="O4" value="0.169" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.145" spread="0.034"/>
                    <measurement group_id="O2" value="0.189" spread="0.034"/>
                    <measurement group_id="O3" value="0.193" spread="0.034"/>
                    <measurement group_id="O4" value="0.180" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3517</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.044</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.049</ci_lower_limit>
            <ci_upper_limit>0.138</ci_upper_limit>
            <estimate_desc>2 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3171</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.048</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.046</ci_lower_limit>
            <ci_upper_limit>0.143</ci_upper_limit>
            <estimate_desc>5 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4654</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.035</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.060</ci_lower_limit>
            <ci_upper_limit>0.130</ci_upper_limit>
            <estimate_desc>10 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEF (Unsupervised) AUC(6-12h) Response [L/Min] After First Administration and 1,2 and 4 Weeks of Treatment</title>
        <description>PEF (peak expiratory flow rate L/min) AUC(6-12h) response is defined as change from the baseline value. AUC(6-12h) will be calculated as the area under the curve from 6 to 12 hours on the various test days using the trapezoidal rule, divided by the full duration (6 hours) to report in litres/min. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on ANCOVA with terms for baseline, treatment, and centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
        <time_frame>6 h, 9 h and 12 h after inhalation at baseline and after 1 week, 2 weeks and 4 weeks</time_frame>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>PEF (Unsupervised) AUC(6-12h) Response [L/Min] After First Administration and 1,2 and 4 Weeks of Treatment</title>
          <description>PEF (peak expiratory flow rate L/min) AUC(6-12h) response is defined as change from the baseline value. AUC(6-12h) will be calculated as the area under the curve from 6 to 12 hours on the various test days using the trapezoidal rule, divided by the full duration (6 hours) to report in litres/min. Baseline was defined as the mean of the 2 pre-treatment values measured at Visit 2 (-1 h and -10 min) prior to administration of the first dose of study medication.
The means are adjusted, based on ANCOVA with terms for baseline, treatment, and centre (centre random, all other effects fixed).
Comparisons between groups are presented for Day 29.</description>
          <population>Full Analysis Set.</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.261" spread="5.245"/>
                    <measurement group_id="O2" value="41.838" spread="5.197"/>
                    <measurement group_id="O3" value="45.179" spread="5.253"/>
                    <measurement group_id="O4" value="41.852" spread="5.360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.139" spread="5.690"/>
                    <measurement group_id="O2" value="47.625" spread="5.643"/>
                    <measurement group_id="O3" value="48.503" spread="5.704"/>
                    <measurement group_id="O4" value="47.924" spread="5.819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.512" spread="5.680"/>
                    <measurement group_id="O2" value="42.179" spread="5.627"/>
                    <measurement group_id="O3" value="52.249" spread="5.688"/>
                    <measurement group_id="O4" value="45.798" spread="5.803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.396" spread="5.469"/>
                    <measurement group_id="O2" value="41.502" spread="5.438"/>
                    <measurement group_id="O3" value="48.212" spread="5.497"/>
                    <measurement group_id="O4" value="47.289" spread="5.606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0899</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>13.106</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.704</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.055</ci_lower_limit>
            <ci_upper_limit>28.267</ci_upper_limit>
            <estimate_desc>2 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0111</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>19.817</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.759</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.549</ci_lower_limit>
            <ci_upper_limit>35.084</ci_upper_limit>
            <estimate_desc>5 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0166</p_value>
            <method>ANCOVA</method>
            <method_desc>terms for baseline, treatment, centre (centre random, all other effects fixed)</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>18.893</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.844</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.458</ci_lower_limit>
            <ci_upper_limit>34.329</ci_upper_limit>
            <estimate_desc>10 µg Olodaterol + 5 µg Tiotropium minus 5 µg Tiotropium.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean Pre-dose Morning PEF [L/Min]</title>
        <description>The patient will record twice daily peak flow measurements using an Asthma Monitor®Am2+ (AM2+) device. Morning measurements will be performed immediately upon arising after the patient has cleared out mucus, prior to administration of trial and/or rescue medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).</description>
        <time_frame>Throughout the 4 week treatment period</time_frame>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Pre-dose Morning PEF [L/Min]</title>
          <description>The patient will record twice daily peak flow measurements using an Asthma Monitor®Am2+ (AM2+) device. Morning measurements will be performed immediately upon arising after the patient has cleared out mucus, prior to administration of trial and/or rescue medication.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).</description>
          <population>Full Analysis Set.</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227.81" spread="3.198"/>
                    <measurement group_id="O2" value="244.43" spread="3.208"/>
                    <measurement group_id="O3" value="248.84" spread="3.174"/>
                    <measurement group_id="O4" value="248.76" spread="3.310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228.57" spread="3.401"/>
                    <measurement group_id="O2" value="240.87" spread="3.415"/>
                    <measurement group_id="O3" value="249.99" spread="3.377"/>
                    <measurement group_id="O4" value="247.77" spread="3.524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228.82" spread="3.663"/>
                    <measurement group_id="O2" value="239.61" spread="3.684"/>
                    <measurement group_id="O3" value="249.39" spread="3.639"/>
                    <measurement group_id="O4" value="248.33" spread="3.800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226.49" spread="3.678"/>
                    <measurement group_id="O2" value="234.14" spread="3.699"/>
                    <measurement group_id="O3" value="249.17" spread="3.654"/>
                    <measurement group_id="O4" value="247.30" spread="3.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean Evening PEF [L/Min]</title>
        <description>The patient will record twice daily peak flow measurements using an AM2+ device. The evening measurement will be performed at bedtime.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).</description>
        <time_frame>Throughout the 4 weeks treatment period</time_frame>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Evening PEF [L/Min]</title>
          <description>The patient will record twice daily peak flow measurements using an AM2+ device. The evening measurement will be performed at bedtime.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).</description>
          <population>Full Analysis Set.</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249.10" spread="3.419"/>
                    <measurement group_id="O2" value="260.86" spread="3.425"/>
                    <measurement group_id="O3" value="267.47" spread="3.360"/>
                    <measurement group_id="O4" value="268.58" spread="3.510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247.10" spread="3.804"/>
                    <measurement group_id="O2" value="260.73" spread="3.814"/>
                    <measurement group_id="O3" value="267.31" spread="3.738"/>
                    <measurement group_id="O4" value="266.40" spread="3.909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249.78" spread="3.765"/>
                    <measurement group_id="O2" value="258.20" spread="3.791"/>
                    <measurement group_id="O3" value="268.16" spread="3.702"/>
                    <measurement group_id="O4" value="265.67" spread="3.884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246.77" spread="3.777"/>
                    <measurement group_id="O2" value="253.12" spread="3.803"/>
                    <measurement group_id="O3" value="266.61" spread="3.714"/>
                    <measurement group_id="O4" value="265.50" spread="3.896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weekly Mean Number of Occasions of Rescue Therapy Used Per Day</title>
        <description>The means are adjusted, Based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).</description>
        <time_frame>Throughout the 4 weeks treatment period</time_frame>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Weekly Mean Number of Occasions of Rescue Therapy Used Per Day</title>
          <description>The means are adjusted, Based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).</description>
          <population>Full Analysis Set.</population>
          <units>occasion(s)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.905" spread="0.155"/>
                    <measurement group_id="O2" value="1.512" spread="0.155"/>
                    <measurement group_id="O3" value="1.504" spread="0.152"/>
                    <measurement group_id="O4" value="1.669" spread="0.159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.784" spread="0.178"/>
                    <measurement group_id="O2" value="1.610" spread="0.177"/>
                    <measurement group_id="O3" value="1.476" spread="0.175"/>
                    <measurement group_id="O4" value="1.477" spread="0.182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.947" spread="0.183"/>
                    <measurement group_id="O2" value="1.650" spread="0.182"/>
                    <measurement group_id="O3" value="1.492" spread="0.180"/>
                    <measurement group_id="O4" value="1.563" spread="0.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.017" spread="0.172"/>
                    <measurement group_id="O2" value="1.615" spread="0.172"/>
                    <measurement group_id="O3" value="1.602" spread="0.169"/>
                    <measurement group_id="O4" value="1.482" spread="0.176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician’s Global Evaluation</title>
        <description>Measured a 8-point scale, from 1 (poor) to 8 (excellent), as judged by the physician, over 4 weeks of treatment.
The physician made a global evaluation at the end of the Baseline Period (Test Day 1) and at each visit thereafter. These assessments were made prior to pulmonary function testing and reflected the physician’s opinion of the patient's overall clinical condition. This evaluation was based on the need for concomitant medication, number and severity of COPD exacerbations since the last visit, severity of cough, ability to exercise, amount of wheezing, and other relevant clinical observations.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).</description>
        <time_frame>1 week, 2 weeks and 4 weeks</time_frame>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Physician’s Global Evaluation</title>
          <description>Measured a 8-point scale, from 1 (poor) to 8 (excellent), as judged by the physician, over 4 weeks of treatment.
The physician made a global evaluation at the end of the Baseline Period (Test Day 1) and at each visit thereafter. These assessments were made prior to pulmonary function testing and reflected the physician’s opinion of the patient's overall clinical condition. This evaluation was based on the need for concomitant medication, number and severity of COPD exacerbations since the last visit, severity of cough, ability to exercise, amount of wheezing, and other relevant clinical observations.
The means are adjusted, based on an ANCOVA with terms for baseline, treatment, centre (centre random, all other effects fixed).</description>
          <population>Full Analysis Set.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.139" spread="0.102"/>
                    <measurement group_id="O2" value="5.102" spread="0.102"/>
                    <measurement group_id="O3" value="5.185" spread="0.100"/>
                    <measurement group_id="O4" value="5.149" spread="0.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.272" spread="0.113"/>
                    <measurement group_id="O2" value="5.130" spread="0.113"/>
                    <measurement group_id="O3" value="5.382" spread="0.111"/>
                    <measurement group_id="O4" value="5.104" spread="0.113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.264" spread="0.115"/>
                    <measurement group_id="O2" value="5.295" spread="0.115"/>
                    <measurement group_id="O3" value="5.447" spread="0.113"/>
                    <measurement group_id="O4" value="5.252" spread="0.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient’s Global Rating</title>
        <description>Patient’s Global Rating at the end of the 4 week treatment period.
Patients rated their health (respiratory condition) at Day 29 (compared to the day before they commenced treatment with study medication) on a 7-point scale as “very much better (1), much better (2), a little better (3), no change (4), a little worse (5), much worse (6), or very much worse (7)”. The assessment was made prior to pulmonary function testing and all other study procedures. The Patient’s Global Rating was also completed before the Physician’s Global Evaluation.
The means are adjusted, based on an ANCOVA with terms for treatment, centre (centre random, treatment effect fixed).</description>
        <time_frame>4 weeks</time_frame>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient’s Global Rating</title>
          <description>Patient’s Global Rating at the end of the 4 week treatment period.
Patients rated their health (respiratory condition) at Day 29 (compared to the day before they commenced treatment with study medication) on a 7-point scale as “very much better (1), much better (2), a little better (3), no change (4), a little worse (5), much worse (6), or very much worse (7)”. The assessment was made prior to pulmonary function testing and all other study procedures. The Patient’s Global Rating was also completed before the Physician’s Global Evaluation.
The means are adjusted, based on an ANCOVA with terms for treatment, centre (centre random, treatment effect fixed).</description>
          <population>Full Analysis Set.</population>
          <units>units on a patient's global rating score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.866" spread="0.112"/>
                    <measurement group_id="O2" value="2.598" spread="0.111"/>
                    <measurement group_id="O3" value="2.368" spread="0.109"/>
                    <measurement group_id="O4" value="2.377" spread="0.113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Anormalities (Laboratory Data); Marked Changes From Baseline for Vital Signs, Notable Change in ECG and New Onset of ECG Abnormalities</title>
        <description>Possible clinically significant anormalities (laboratory data); marked changes from baseline for vital signs, notable change in ECG and new onset of ECG abnormalities. New abnormal findings or worsening of baseline conditions were reported as Adverse Events (AEs).
All AEs with an onset after the first dose of study medication up to 21 days after the last dose of study medication were to have been assigned to the Treatment Period.</description>
        <time_frame>From first dose up to 21 days after last dose of study medication.</time_frame>
        <population>Treated Set.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Anormalities (Laboratory Data); Marked Changes From Baseline for Vital Signs, Notable Change in ECG and New Onset of ECG Abnormalities</title>
          <description>Possible clinically significant anormalities (laboratory data); marked changes from baseline for vital signs, notable change in ECG and new onset of ECG abnormalities. New abnormal findings or worsening of baseline conditions were reported as Adverse Events (AEs).
All AEs with an onset after the first dose of study medication up to 21 days after the last dose of study medication were to have been assigned to the Treatment Period.</description>
          <population>Treated Set.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax,ss Olodaterol [pg/mL]</title>
        <description>Maximum measured concentration of Olodaterol in plasma at steady state (Cmax,ss) after 4 weeks of treatment.
No results displayed for Tiotropium+Olodaterol 5/2 μg because there were zero total participants analyzed for this outcome measure.</description>
        <time_frame>Pre-dose, 5 min, 10 min, 20 min, 40 min, 1 h, 3 h, and 6 h after the last dose.</time_frame>
        <population>Evaluable patients. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK or had insufficient data.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax,ss Olodaterol [pg/mL]</title>
          <description>Maximum measured concentration of Olodaterol in plasma at steady state (Cmax,ss) after 4 weeks of treatment.
No results displayed for Tiotropium+Olodaterol 5/2 μg because there were zero total participants analyzed for this outcome measure.</description>
          <population>Evaluable patients. A patient was considered to be not evaluable if the patient had a protocol violation relevant to the evaluation of PK or had insufficient data.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.39" spread="49.2"/>
                    <measurement group_id="O2" value="6.87" spread="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax,ss Olodaterol [h]</title>
        <description>Time from last dosing to maximum concentration of Olodaterol in plasma at steady state (tmax,ss) after 4 weeks treatment.
No results displayed for Tiotropium+Olodaterol 5/2 μg because there were zero total participants analyzed for this outcome measure.</description>
        <time_frame>Pre-dose, 5 min, 10 min, 20 min, 40 min, 1 h, 3 h, and 6 h after the last dose.</time_frame>
        <population>Evaluable patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax,ss Olodaterol [h]</title>
          <description>Time from last dosing to maximum concentration of Olodaterol in plasma at steady state (tmax,ss) after 4 weeks treatment.
No results displayed for Tiotropium+Olodaterol 5/2 μg because there were zero total participants analyzed for this outcome measure.</description>
          <population>Evaluable patients.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.167" lower_limit="0.083" upper_limit="0.917"/>
                    <measurement group_id="O2" value="0.183" lower_limit="0.067" upper_limit="1.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-1h,ss) Olodaterol [pg*h/mL]</title>
        <description>Area under the concentration-time curve of Olodaterol in plasma at steady state (AUC(0-1h,ss)) from 0 to 1 hour post dosing after 4 weeks of treatment.
No results displayed for Tiotropium+Olodaterol 5/2 μg because there were zero total participants analyzed for this outcome measure.</description>
        <time_frame>Pre-dose, 5 min, 10 min, 20 min, 40 min, 1 h, 3 h, and 6 h after the last dose.</time_frame>
        <population>Evaluable patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-1h,ss) Olodaterol [pg*h/mL]</title>
          <description>Area under the concentration-time curve of Olodaterol in plasma at steady state (AUC(0-1h,ss)) from 0 to 1 hour post dosing after 4 weeks of treatment.
No results displayed for Tiotropium+Olodaterol 5/2 μg because there were zero total participants analyzed for this outcome measure.</description>
          <population>Evaluable patients.</population>
          <units>pg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.97" spread="49.4"/>
                    <measurement group_id="O2" value="5.82" spread="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax,ss Tiotropium [pg/mL]</title>
        <description>Maximum measured concentration of Tiotropium in plasma at steady state (Cmax,ss) after 4 weeks treatment.</description>
        <time_frame>Pre-dose, 5 min, 10 min, 20 min, 40 min, 1 h, 3 h, and 6 h after the last dose.</time_frame>
        <population>Evaluable patients.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax,ss Tiotropium [pg/mL]</title>
          <description>Maximum measured concentration of Tiotropium in plasma at steady state (Cmax,ss) after 4 weeks treatment.</description>
          <population>Evaluable patients.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="75.3"/>
                    <measurement group_id="O2" value="13.9" spread="64.7"/>
                    <measurement group_id="O3" value="12.4" spread="69.7"/>
                    <measurement group_id="O4" value="14.4" spread="69.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax,ss Tiotropium [h]</title>
        <description>Time from last dosing to maximum concentration of Tiotropium in plasma at steady state (tmax,ss) after 4 weeks of treatment.</description>
        <time_frame>Pre-dose, 5 min, 10 min, 20 min, 40 min, 1 h, 3 h, and 6 h after the last dose.</time_frame>
        <population>Evaluable patients.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax,ss Tiotropium [h]</title>
          <description>Time from last dosing to maximum concentration of Tiotropium in plasma at steady state (tmax,ss) after 4 weeks of treatment.</description>
          <population>Evaluable patients.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.133" lower_limit="0.050" upper_limit="1.000"/>
                    <measurement group_id="O2" value="0.100" lower_limit="0.017" upper_limit="0.983"/>
                    <measurement group_id="O3" value="0.083" lower_limit="0.067" upper_limit="0.917"/>
                    <measurement group_id="O4" value="0.133" lower_limit="0.050" upper_limit="1.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-3h,ss) Tiotropium [pg*h/mL]</title>
        <description>Area under the concentration-time curve of Tiotropium at steady state (AUC(0-3h,ss)) from 0 to 3 hours post dosing after 4 weeks of treatment.</description>
        <time_frame>Pre-dose, 5 min, 10 min, 20 min, 40 min, 1 h, 3 h, and 6 h after the last dose.</time_frame>
        <population>Evaluable patients.</population>
        <group_list>
          <group group_id="O1">
            <title>5 µg Tiotropium</title>
            <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium+Olodaterol 5/2 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium+Olodaterol 5/5 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium+Olodaterol 5/10 μg</title>
            <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-3h,ss) Tiotropium [pg*h/mL]</title>
          <description>Area under the concentration-time curve of Tiotropium at steady state (AUC(0-3h,ss)) from 0 to 3 hours post dosing after 4 weeks of treatment.</description>
          <population>Evaluable patients.</population>
          <units>pg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8" spread="42.8"/>
                    <measurement group_id="O2" value="21.9" spread="45.3"/>
                    <measurement group_id="O3" value="21.9" spread="47.9"/>
                    <measurement group_id="O4" value="21.0" spread="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose up to 21 days after last dose of study medication, upto 86 days.</time_frame>
      <desc>At each visit, all AEs, regardless of causality, were recorded on the AE e-CRF page after review of the e-Diary and discussion with the patient. Adverse events were recorded on the eCRFs as non-serious or SAEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>5 µg Tiotropium</title>
          <description>Oral inhalation of Tiotropium fixed dose 5 µg (2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="E2">
          <title>Tiotropium+Olodaterol 5/2 μg</title>
          <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 2 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 1.0 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="E3">
          <title>Tiotropium+Olodaterol 5/5 μg</title>
          <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 5 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 2.5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="E4">
          <title>Tiotropium+Olodaterol 5/10 μg</title>
          <description>Oral inhalation of FDC of Tiotropium 5 µg and Olodaterol 10 µg (Tiotropium: 2.5 µg per actuation and Olodaterol: 5 µg per actuation), 2 puffs from the Respimat inhaler, once daily, in the morning.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Additional secondary endpoints were listed in the original protocol. Those endpoints are of exploratory nature only and were not considered relevant for trial conclusions. For more information see tab “Full Text Review”, section “More Information&quot;.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

